naproxen has been researched along with phencyclidine in 5 studies
Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (phencyclidine) | Trials (phencyclidine) | Recent Studies (post-2010) (phencyclidine) |
---|---|---|---|---|---|
4,551 | 1,057 | 1,429 | 28,294 | 387 | 7,796 |
Protein | Taxonomy | naproxen (IC50) | phencyclidine (IC50) |
---|---|---|---|
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 0.1299 | |
Lysosomal Pro-X carboxypeptidase | Homo sapiens (human) | 0.091 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.1299 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.1299 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.1299 | |
Glutamate receptor ionotropic, NMDA 1 | Homo sapiens (human) | 0.5563 | |
Glutamate receptor ionotropic, NMDA 2A | Homo sapiens (human) | 0.205 | |
Glutamate receptor ionotropic, NMDA 2B | Homo sapiens (human) | 1.2589 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.1299 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.1299 | |
Sigma non-opioid intracellular receptor 1 | Rattus norvegicus (Norway rat) | 0.53 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.1299 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (60.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jolivette, LJ; Ward, KW | 1 |
Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
Barker, SA | 1 |
Koga, A; Kubota, R; Maeda, H; Ohta, T; Terada, K | 1 |
5 other study(ies) available for naproxen and phencyclidine
Article | Year |
---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
Drug contamination of the equine racetrack environment: a preliminary examination.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Clonixin; Dust; Environmental Pollutants; Fresh Water; Gas Chromatography-Mass Spectrometry; Horses; Housing, Animal; Naproxen; Pharmaceutical Preparations; Phenylbutazone; Soil | 2008 |
Establishment of powder dustiness evaluation method by dustmeter with small amount of pharmaceutical ingredients.
Topics: Dust; Lactose; Naproxen; Particle Size; Powders; Technology, Pharmaceutical | 2014 |